A new serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels.

Swan, F.; Velasquez, William S.; Tucker, Susan L.; Redman, John R.; Rodriguez, Maria Alma; McLaughlin, Peter; Hagemeister, Fredrick B.; Cabanillas, Fernando

doi:10.1200/jco.1989.7.10.1518

Cited by 142 publications

(51 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, serum ␤ 2 -microglobulin was the only covariate that correlated with the percentage of bone marrow blasts. These results, together with the known prognostic importance of ␤ 2 -microglobulin in myeloma, 43 lymphoma, 44 and chronic lymphocytic leukemia, 45 encourage extended investigation of the influence of this covariate in CMML.…”

Section: Discussionmentioning

confidence: 99%

Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients

Onida

Kantarjian

Smith

et al. 2002

Blood

344

304

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients

Onida

Kantarjian

Smith

et al. 2002

Blood

344

304

View full text Add to dashboard Cite

“…The clinical significance of serum h2M levels in AML may be explained as previously described in non -Hodgkin's lymphoma (14). h2M and HLA molecules are variably expressed on the surface of tumor cells (43 -46).…”

Section: Discussionmentioning

confidence: 99%

The Prognostic Significance of Serum β2 Microglobulin Levels in Acute Myeloid Leukemia and Prognostic Scores Predicting Survival: Analysis of 1,180 Patients

Tsimberidou¹,

Kantarjian²,

Wen

et al. 2008

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Serum h 2 microglobulin (h2M) is prognostic in other hematologic malignancies; therefore, we evaluated its prognostic significance in acute myeloid leukemia (AML). Experimental Design: Multivariate analyses were used to examine the effect of pretreatment serum h2M levels on clinical outcomes in patients with AML. h2M was associated with poorer survival in older but not younger patients. We thus fit separate Cox survival models in patients above and below age 60 years treated with remission induction therapy containing high-dose cytarabine (n = 1,280). In each age group, 50% of the patients were used to develop the model, which was tested in the other 50%. Resampling methods were also used to validate the independent prognostic significance of covariates. Results: In patients 60 years or older (n = 591), poorer risk cytogenetics; poorer performance status; and higher levels of h2M, uric acid, and lactate dehydrogenase were each found to independently predict shorter survival and formed the basis of a scoring system. A similar approach was used in patients younger than 60 years (n = 589), with poorer risk cytogenetics, poorer performance status, older age, higher hemoglobin level, and higher leukocyte count predicting a shorter survival and forming the basis of the scoring system. Higher h2M levels were an adverse independent factor for response, survival, relapse-free survival, and event-free survival in older but not in younger patients. Conclusions: Serum h2M levels can help predict outcome in patients z60 years with untreated AML, and their use is strongly encouraged.

show abstract

“…26 Despite normal renal function in patients, elevated serum levels of ␤-2M, have been associated with a large tumor burden and a poor prognosis in patients with several lymphoid malignancies, including multiple myeloma, B-cell non-Hodgkin lymphoma, and chronic lymphocytic leukemia. [27][28][29][30] A number of groups have also reported that serum ␤-2M levels correlate with Ann Arbor stage and the presence of B symptoms in patients with Hodgkin disease and that elevated levels of this polypeptide predict a less favorable prognosis.…”

Section: Discussionmentioning

confidence: 99%

An elevated serum beta‐2‐microglobulin level is an adverse prognostic factor for overall survival in patients with early‐stage Hodgkin disease

Chronowski

Wilder

Tucker

et al. 2002

Cancer

View full text Add to dashboard Cite

BACKGROUNDThe relative importance of prognostic factors in patients with early‐stage Hodgkin disease remains controversial. The purpose of this study was to evaluate prognostic factors among patients who received chemotherapy before radiotherapy.METHODSFrom 1987 to 1995, 217 consecutive patients ranging in age from 16 to 88 years (median, 28 years) with Ann Arbor Stage I (n = 55) or II (n = 162) Hodgkin disease underwent chemotherapy before radiotherapy at a single center. Most were treated on prospective studies. Patients received a median of three cycles of induction chemotherapy. Mitoxantrone, vincristine, vinblastine, and prednisone (NOVP), doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), mechlorethamine, vincristine, procarbazine, and prednisone (MOPP), cyclophosphamide, vinblastine, procarbazine, prednisone, doxorubicin, bleomycin, dacarbazine, and CCNU (CVPP/ABDIC), or other chemotherapeutic regimens were given to 160, 18, 15, 10, and 14 patients, respectively. The median radiotherapy dose was 40 Gy. Serum β‐2‐microglobulin (β‐2M) levels ranged from 1.0 to 4.1 mg/L (median, 1.7 mg/L; upper limit of normal, 2.0 mg/L). We studied univariate and multivariate associations between survival and the following clinical features: serum β‐2M level above 1.25 times the upper limit of normal (n = 12), male gender (n = 113), hypoalbuminemia (n = 11), and bulky mediastinal disease (n = 94).RESULTSFollow‐up of surviving patients ranged from 0.9 to 13.4 years (median, 6.6 years) and 92% were observed for 3.0 or more years. Nineteen patients have died. Only elevation of the serum β‐2M level was an independent adverse prognostic factor for overall survival (P = 0.0009).CONCLUSIONSThe prognostic significance of a simple, widely available, and inexpensive blood test, β‐2M, has not been studied routinely in patients with Hodgkin disease and should be tested prospectively in large, cooperative group trials. Cancer 2002;95:2534–8. © 2002 American Cancer Society.DOI 10.1002/cncr.10998

show abstract

A new serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels.

Cited by 142 publications

References 49 publications

Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients

Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients

The Prognostic Significance of Serum β2 Microglobulin Levels in Acute Myeloid Leukemia and Prognostic Scores Predicting Survival: Analysis of 1,180 Patients

An elevated serum beta‐2‐microglobulin level is an adverse prognostic factor for overall survival in patients with early‐stage Hodgkin disease

Contact Info

Product

Resources

About